BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31841816)

  • 21. Assessment of the effect of therapy in a rat model of glioblastoma using [18F]FDG and [18F]FCho PET compared to contrast-enhanced MRI.
    Bolcaen J; Descamps B; Deblaere K; De Vos F; Boterberg T; Hallaert G; Van den Broecke C; Vanhove C; Goethals I
    PLoS One; 2021; 16(3):e0248193. PubMed ID: 33667282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Technical feasibility of [
    Verhoeven J; Bolcaen J; De Meulenaere V; Kersemans K; Descamps B; Donche S; Van den Broecke C; Boterberg T; Kalala JP; Deblaere K; Vanhove C; De Vos F; Goethals I
    Radiat Oncol; 2019 May; 14(1):89. PubMed ID: 31146757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel
    Hanaoka H; Ohshima Y; Yamaguchi A; Suzuki H; Ishioka NS; Higuchi T; Arano Y; Tsushima Y
    Mol Pharm; 2019 Aug; 16(8):3609-3616. PubMed ID: 31242385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among
    Tomura N; Kokubun M; Saginoya T; Mizuno Y; Kikuchi Y
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1520-1527. PubMed ID: 28619837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
    Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
    Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed [ 18 F]-FDG PET Imaging Increases Diagnostic Performance and Reproducibility to Differentiate Recurrence of Brain Metastases From Radionecrosis.
    Otman H; Farce J; Meneret P; Palard-Novello X; Le Reste PJ; Lecouillard I; Vauleon E; Chanchou M; Carsin Nicol B; Bertaux M; Devillers A; Mariano-Goulart D; Cachin F; Girard A; Le Jeune F
    Clin Nucl Med; 2022 Sep; 47(9):800-806. PubMed ID: 35695724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo PET/CT in a human glioblastoma chicken chorioallantoic membrane model: a new tool for oncology and radiotracer development.
    Warnock G; Turtoi A; Blomme A; Bretin F; Bahri MA; Lemaire C; Libert LC; Seret AE; Luxen A; Castronovo V; Plenevaux AR
    J Nucl Med; 2013 Oct; 54(10):1782-8. PubMed ID: 23970367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.
    Nedergaard MK; Michaelsen SR; Perryman L; Erler J; Poulsen HS; Stockhausen MT; Lassen U; Kjaer A
    Nucl Med Biol; 2016 Mar; 43(3):198-205. PubMed ID: 26924500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation.
    van Waarde A; Jager PL; Ishiwata K; Dierckx RA; Elsinga PH
    J Nucl Med; 2006 Jan; 47(1):150-4. PubMed ID: 16391199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
    Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
    J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats.
    Bolcaen J; Descamps B; Acou M; Deblaere K; den Broecke CV; Boterberg T; Vanhove C; Goethals I
    Mol Imaging Biol; 2017 Dec; 19(6):857-866. PubMed ID: 28303489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.
    Spaeth N; Wyss MT; Weber B; Scheidegger S; Lutz A; Verwey J; Radovanovic I; Pahnke J; Wild D; Westera G; Weishaupt D; Hermann DM; Kaser-Hotz B; Aguzzi A; Buck A
    J Nucl Med; 2004 Nov; 45(11):1931-8. PubMed ID: 15534065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of Dynamic O-(2-[
    Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
    World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
    Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic
    Lim W; Acker G; Hardt J; Kufeld M; Kluge A; Brenner W; Conti A; Budach V; Vajkoczy P; Senger C; Prasad V
    Cancer Treat Res Commun; 2022; 32():100583. PubMed ID: 35688103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison study of dynamic [
    Pan Y; Dang H; Zhou H; Fu H; Wu S; Liu H; Zhang J; Wang R; Tian Y; Xu B
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):208. PubMed ID: 38647690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis.
    Siepmann DB; Siegel A; Lewis PJ
    Clin Nucl Med; 2005 Mar; 30(3):199-200. PubMed ID: 15722830
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
    Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
    Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.